The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
@StarBright & Kingsley, Here's some homework for you - watch and listen to the CC presentation.
I don't think this RNS will do much for the share price short term given the mentality of AIM and the London market - probably a spike - but does a lot for the company's, and hence the share price's, long term prospects.
@Harrogate4, It's an Alan joke.
@Kingsley, Nice, maybe you'll meet sheppy there in the mirror.
"Even Alan can't feck this up tomorrow night."
SP 100p by 4:30 tomorrow, open 50p Thursday.
@CTSFO , route is pivotal Phase 2, provisonal regulatory approval and marketting, Phase 3 to check(finally prove) that it works. If Phase 3 were to fail, marketting approval would be revoked.
60-year-old male patient with a right-side popliteal mass biopsy diagnosed with a grade 3 undifferentiated pleomorphic sarcoma (UPS). Prior cancer therapy preoperative radiotherapy (May-Jul 2021) followed by surgery (Sept 2021, viable tumour cells in less than 10% of tumor volume). Stage IV diagnosis (March 2022) with pleural metastases, enrolled in etigilimab + nivolimab (clinical trial June 2022-Jan 2023) with disease progression prior to enrolling in the AVA6000 phase 1 trial
Moral of the story: Never give up hope
Case Study:
60-year-old male patient with a right-side popliteal mass biopsy diagnosed with a grade 3 undifferentiated pleomorphic sarcoma (UPS). Prior cancer therapy preoperative radiotherapy (May-Jul 2021) followed by surgery (Sept 2021, viable tumour cells in
Ah.
To get your thoughts on what? The Phase 1a Q3W data? Your voting intention? The price of fish?
Why did TP call?
SP back to where it was 4:30, Friday, and AS yet to speak.
@CTSFO, No. 120mg/m² was C3. No MTD was found in any of the seven cohorts up to 385mg/m² (RNS of 21 March).
What is this strange ACCR of which you speak oh wondrous Bot? Is it that Avacta are joining Automóvil Club de Costa Rica?
Moron
Could be SIPP trades. No limit there except earnings.
Full data release will be in the peer reviewed paper, Avacta's first pre|CISION peer reviewed paper. If it is ever published.
As far as I can see, Avacta's plans, as described in the RNS of 28 February (the infamous one) and the updated website, consist of nothing more than progressing AVA6000 in an admirably thorough way, getting AVA3996 to the submitting an IND/CTA application stage a year later than originally planned, and a lot of fluff (AS waffle) about whatever else might happen over the next 18 months to two years.
https://www.lse.co.uk/rns/AVCT/proposed-fundraise-to-progress-therapeutics-pa5q71zfw9lgspt.html
https://avacta.com/precision/pipeline/
I wonder how the DX expansion into Germany is going.
Corrected for you Bella. No need to thank me.
Now, what was that new position announcement I saw a couple of days ago on LinkedIn about...🤔
I don't know whether this pre|CISION™ ADC approach should be termed Search & Destroy or Belt & Braces. Nor how much more effective than pre|CISION™ alone it could be - PK, etc. data for pre|CISION™ will tell that.
One thing's for sure: it would be a lot more targetted than cleavable ADCs alone and that's perhaps the point as there are lot of invested resources already thrown at ADCs.
There was a lot in that review, too much to quote or even to point towards. But one takeaway I had was tha tthe toxic side effects are due to the warhead, irrespective of the mAb and what the mAb is targetted at. That means that either the warhead is active when attached to the mAb or, most commonly, the warhead is non-specifically cleaved off by enzymes or acidity and so is able to roam free within the body. pre|CISION's exquisite specificity is a whole step change up in reducing such toxicity.
Tookanarkman wrote "What does “AVA6000 distributes rapidly with a t1/2 of 45 min” actually mean? "
"AVA6000" means Avacta's drug undergoing Phase 1a trial
"distributes rapidly" means distributes rapidly
"t1/2" means half-life
"45 min" means three quaters of an hour
As I remember, AS said there was a problem with the practical application of FAPi-PET in both access (only available from a few places) and timeliness (short half-life of the radioactive diagnostics).